BioNTech Investor Day Presentation Deck
Combination of PD-L1x4-1BB bispecific with PD-1 blockade
improves activity in preclinical models
Median tumor volume per treatment group (n=10)¹
Median tumor volume, mm³
2500
2000
1500
1000
50
14
21
Time, d
28
35
PBS
Anti-mPD-1 (10 mg/kg) bs anti-mPD-L1xm4-1BB (5 mg/kg)
bs anti-mPD-L1xm4-1BB (5 mg/kg) + anti-mPD-1 (10 mg/kg) ▼ Treatment
Mice with tumor volume
<500 mm³, %
100
80
60
40
20
0-
Survival²
14
21
Time, d
PBS
Anti-mPD-1 (10 mg/kg) bs anti-mPD-L1xm4-1BB (5 mg/kg)
bs anti-mPD-L1xm4-1BB (5 mg/kg) + anti-mPD-1 (10 mg/kg) ▼ Treatment
28
35
Complete tumor regression in 7/10 mice and significant enhancement of survival
1 Growth curves were discontinued when <50% of the animals within a treatment group remained alive or at day 35; 2 Defined as the percentage of mice with tumor volumes <500 mm³.
Mantel-Cox analysis on day 45: PBS vs anti-m PD-1: p=0.012, PBS vs anti-m PD-L1xm4-1BB: p<0.001, PBS vs anti-m PD-L1xm4-1BB+ anti-m PD-1: p<0.001, anti-m PD-1 vs anti-m PD-L1xm4-1BB: p=0.5;
anti-m PD-1 vs anti-m PD-L1xm4-1BB+ anti-m PD-1: p=0.001; anti-m PD-L1xm4-1BB vs anti-m PD-L1xm4-1BB+ anti-m PD-1: p<0.001.
Ponce Aix S, et al. SITC Annual Meeting 2021; Poster presentation 516.
Protein therapeutics
42
BIONTECH
122View entire presentation